Ryu J M, Chung S J, Lee M H, Kim C K
Department of Pharmaceutics, College of Pharmacy, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul 151-742, South Korea.
J Control Release. 1999 May 20;59(2):163-72. doi: 10.1016/s0168-3659(98)00189-8.
Mucoadhesive liquid suppositories were prepared by adding mucoadhesive polymers (0.6%) to a formulation of thermally gelling suppositories that contained poloxamer 407 (15%), poloxamer 188 (15%) and propranolol HCl (2%). Hydroxypropylcellulose (HPC), polyvinylpyrrolidone (PVP), carbopol, polycarbophil and sodium alginate were examined as mucoadhesive polymers. The characteristics of the suppositories differed depending on the choice of mucoadhesive polymer. For example, the gelation temperature was between 30 and 36 degrees C, the mucoadhesive force was between 430 and 5800 dyne/cm2, the apparent first-order release rate constant in phosphate buffer, pH 6.8, was between 0.399 and 0.271 h-1, the migration distance of the suppository in the rectum 4 h after administration was between 1 and 5 cm, and the bioavailability of propranolol was between 60.9 and 84.7%. Rectal bioavailability increased as the mucoadhesive force increased (r=0.984, p<0.0005), and the migration distance decreased (r=-0.951, p<0.005). No relationship was found between the bioavailability and the gelation temperature, drug release or irritation of the rectal mucosal membrane by the suppository. Therefore, retaining propranolol at the dosed site in the rectum by the addition of appropriate mucoadhesives to the formulation of liquid suppositories appears to be a very important factor in avoiding first-pass hepatic elimination and thereby increasing the bioavailability of the drug. Among the mucoadhesive polymers examined, sodium alginate and polycarbophil exhibited the largest mucoadhesive force and the smallest intrarectal migration resulting in the largest bioavailability of propranolol (84.7 and 82.3%, respectively). In contrast to other polymers, sodium alginate alone caused no irritation of the rectal mucosal membrane. Thus, poloxamer liquid suppositories containing sodium alginate appears to be a preferred formulation for drugs that are sensitive to extensive first-pass metabolism.
通过向含有泊洛沙姆407(15%)、泊洛沙姆188(15%)和盐酸普萘洛尔(2%)的热凝胶栓剂配方中添加黏膜黏附聚合物(0.6%)来制备黏膜黏附性液体栓剂。研究了羟丙基纤维素(HPC)、聚乙烯吡咯烷酮(PVP)、卡波姆、聚卡波非和海藻酸钠作为黏膜黏附聚合物的情况。栓剂的特性因黏膜黏附聚合物的选择而异。例如,凝胶化温度在30至36摄氏度之间,黏膜黏附力在430至5800达因/平方厘米之间,在pH 6.8的磷酸盐缓冲液中的表观一级释放速率常数在0.399至0.271 h⁻¹之间,给药后4小时栓剂在直肠中的迁移距离在1至5厘米之间,普萘洛尔的生物利用度在60.9%至84.7%之间。直肠生物利用度随着黏膜黏附力的增加而增加(r = 0.984,p < 0.0005),且迁移距离减小(r = -0.951,p < 0.005)。未发现生物利用度与凝胶化温度、药物释放或栓剂对直肠黏膜的刺激之间存在关联。因此,通过向液体栓剂配方中添加合适的黏膜黏附剂将普萘洛尔保留在直肠给药部位似乎是避免首过肝消除从而提高药物生物利用度的一个非常重要的因素。在所研究的黏膜黏附聚合物中,海藻酸钠和聚卡波非表现出最大的黏膜黏附力和最小的直肠内迁移,从而使普萘洛尔的生物利用度最高(分别为84.7%和82.3%)。与其他聚合物不同,单独的海藻酸钠不会引起直肠黏膜的刺激。因此,含有海藻酸钠的泊洛沙姆液体栓剂似乎是对广泛首过代谢敏感的药物的首选配方。